Webinar : Measuring the Patient’s Perspective of the Benefits of Diabetes Interventions

23rd December 2015

Dr Keith Meadows, author of the Diabetes Health Profile (DHP) will present a webinar on Tuesday February 4th 2016 at 3 p.m. UK (1000 Eastern USA, 1600 Central European).

The Diabetes Health Profile (DHP) – Beyond Blood Glucose / HbA1c

Measuring the Patient’s Perspective of the Benefits of Diabetes Interventions

This webinar is hosted by our associates at MAPI

Developed to measure the psychological and behavioural impact of diabetes in a variety of settings from clinical practice to phase II to IV, the Diabetes Health Profile (DHP) is available in two formats. The DHP-1 comprises 32 items and is for use with Type 1 and insulin requiring, while the DHP-18 is a short, 18 item form, developed for all treatment modalities, insulin, oral and diet. For both formats item responses are summed to provide three domain scores measuring: Psychological distress, Barriers to activity and Disinhibited eating.

Developed using a clearly defined conceptual framework of the measurement model which conforms to the FDA Final guidance for Industry and facilitating the selection of appropriate secondary endpoints, the DHP has been completed internationally by more than 15000 patients in clinical trials, epidemiological studies and primary care. Clinical relevance includes:

• Higher (negative) Barriers to activity scores with people with microvascular complications) and severe hypoglycemia,
• Increased Psychological distress and Barriers to activity with insulin treatment compared to oral hypoglycemic agents and increasing weight
• Higher (negative) Disinhibited eating scores with non-adherence to treatment and increasing weight
• Subscale results comparable with the recommended EQ-5D enabling a holistic assessment of the quality of life impacts of Type 2 diabetes”
• Clinically relevant minimally important change from baseline
• High response rates (60% – 80%)
• Low levels of missing item data (4% – 12%)

The DHP-18 was the measure of choice by the UK Department of Health’s Pilot for Long Term Conditions in Primary Care and has been recommended as the diabetes PRO measure in a National Clinical Audit within the UK NHS.

Following extensive linguistic validation in accordance with ISPOR guidelines and the standards accepted by regulatory agencies such as the FDA, the DHP is available in 30 languages.

The aims of the webinar include:

• An update on the development and availability of the utility weighted version of the DHP
• A summary of the DHP-18 performance in the Long Term Conditions in Primary Care pilot
• An illustration of the responsiveness of the DHP-18, EQ-5D, SF-6D in type 2 diabetes
• Development of the Author Pre-approved eDHP18
• Future developments of the DHP

Who should attend?

• Clinical trialists
• Regulators
• Payers
• Researchers
• Healthcare market researchers

Registration

To register for this webinar follow the link

Press release sign up